Cosmetic, nutritional or dermatological use of lactobacillus crispatus strains and / or compositions comprising same
By using Lactobacillus curl strain to reduce melanin production and tyrosinase activity, combined with antioxidant effects, the problem of skin and mucosal pigmentation is solved, and significant cosmetic effects and safety is achieved. It is suitable for beauty and skin diseases in the elderly population. Learn the purpose.
Patent Information
- Application Number
- CN202380031928.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-03-28
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively reduce pigmentation of the skin and mucosa, especially in the elderly population, and lacks safe and significant efficacy cosmetic active agents to prevent increased pigmentation of the skin and mucosa.
Using Lactobacillus curl strains, especially those preserved by numbered CNCM I-5579, reduces skin and mucous membranes by reducing melanin production and tyrosinase activity, inhibits melanin synthesis, and through antioxidant effects and increasing glutathione synthesis pigmentation and pigmentation spots appear.
Significantly reduce pigmentation in the skin and mucous membranes, improve the gloss and uniformity of skin tone, prevent the appearance and decrease its presence of pigment spots, is safe and easy to manufacture on an industrial scale, suitable for cosmetic and dermatological purposes in the elderly .
Smart Images

Figure BDA0005067220200000271 
Figure BDA0005067220200000281 
Figure BDA0005067220200000301
Abstract
Description
[0001] The present invention relates to the cosmetic, nutritional and / or pharmaceutical use of a Lactobacillus crispatus strain and / or a composition comprising the strain for reducing pigmentation of the skin and / or mucous membranes and / or preventing increased pigmentation of the skin and / or mucous membranes, in particular for dermatological use.
[0002] The structure and appearance of the skin changes with age and / or under the influence of extrinsic and / or intrinsic factors. These changes are of many kinds, including changes in the pigmentation of the skin and / or mucous membranes. The skin becomes duller, less bright, lacks radiance, its radiance decreases, and the skin tone becomes less uniform, with the appearance of pigmented spots.
[0003] The appearance of these changes, such as pigment spots, is accelerated with age or accelerated aging, especially under the effects of radiation (usually UV rays) or pollution. They are associated with the presence of melanin and lipofuscin, whose excess and abnormal distribution in the skin lead to the appearance of brown spots, known as senile or pigmented brown spots, also known as "age spots". These can appear as a marker of accelerated melanin production and are generally considered unsightly. They make the skin tone uneven and dull.
[0004] Melanogenesis and oxidative stress are the subject of numerous studies and innovations in the cosmetic field for the development and improvement of cosmetic actives aimed at reducing and / or preventing increased pigmentation of healthy skin and / or healthy mucous membranes.
[0005] There is a need in the field of cosmetics and dermatology to develop alternative natural active ingredients which are able to reduce pigmentation of the skin and / or mucous membranes and / or prevent increased pigmentation of the skin and / or mucous membranes, in particular to maintain and / or improve the skin tone of the skin and / or mucous membranes, in particular its radiance and / or brightness and / or evenness, in particular in populations more susceptible to the development of pigmented spots, in particular in skin types IV to VI as defined by the Fitzpatrick classification.
[0006] There is a continuing need to identify pharmaceutical agents that possess one or more of these properties, particularly with demonstrated efficacy and safety.
[0007] Particularly surprisingly, the Applicant has discovered that Lactobacillus crispatus, a commensal bacterium beneficial to the skin and / or mucous membranes, has the property of reducing pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular maintaining and / or improving the skin color of the skin and / or mucous membranes, preferably maintaining and / or improving the glossiness and / or brightness and / or evenness of the skin color of the skin and / or mucous membranes, and / or preventing the appearance of pigmented spots on the skin and / or mucous membranes and / or reducing the presence of pigmented spots on the skin and / or mucous membranes.
[0008] The applicant has also surprisingly discovered that this bacterium also has skin and / or mucous membrane detoxifying properties.
[0009] The Applicant's invention is all the more advantageous because the bacterium Lactobacillus crispatus, and in particular the Lactobacillus crispatus deposited under number CNCM 1-5579, has the advantage of being naturally present on young skin, unlike the bacteria used hitherto in cosmetic and / or dermatological treatments.
[0010] The present invention is even more advantageous because the Applicant has demonstrated that with increasing age and / or under the influence of intrinsic and / or extrinsic factors, the bacterium Lactobacillus crispatus is present less and less abundantly on the skin. The subject matter of the present invention therefore has the advantage of rebalancing and / or replenishing the microflora of the skin and / or mucous membranes, in particular with bacteria of the skin flora that decrease and become more rare over time and / or due to exposure to intrinsic and / or extrinsic factors.
[0011] The subject matter of the present invention is therefore particularly suitable for treating the skin of individuals referred to as mature, in particular those over the age of 50 years.
[0012] The strain according to the invention also has the advantage of being an ingredient that is easily formulatable and can be easily manufactured on an industrial scale. It is a topically acceptable active ingredient for the skin and mucous membranes without the risk of allergies.
[0013] Applications have already described the use of Lactobacillus crispatus in cosmetology. Thus, application WO 9822082 discloses the use of sphingomyelinase extractable from lactic acid bacteria for topical application to increase the ceramide levels of the skin and mucous membranes for the preventive or therapeutic treatment of various pathological conditions.
[0014] Application WO 2009031099 discloses the use of probiotics for aesthetic purposes for preventing the onset and / or treating the manifestations of discomfort and / or skin symptoms associated with superficial treatments of the skin or with invasive treatments.
[0015] Application WO 2019 / 111189 describes the use of probiotics, in particular Lactobacillus paracasei, for preventing UV radiation-induced inflammatory damage.
[0016] However, none of these applications discloses or suggests the cosmetic, nutritional and / or pharmaceutical use, in particular dermatological use, of a Lactobacillus crispatus strain and / or a composition comprising the strain for reducing pigmentation of the skin and / or mucous membranes and / or for preventing its increase, in particular for maintaining and / or improving the skin color of the skin and / or mucous membranes, preferably for maintaining and / or improving the glossiness and / or brightness and / or uniformity of the skin color of the skin and / or mucous membranes, and / or for preventing the appearance of pigmented spots on the skin and / or mucous membranes and / or reducing the presence of pigmented spots on the skin and / or mucous membranes.
[0017] Furthermore, none of these applications discloses or suggests the use of a Lactobacillus crispatus strain and / or a composition comprising the strain for detoxifying the skin and / or mucous membranes.
[0018] A first subject of the present invention is the cosmetic and / or nutritional use of a Lactobacillus crispatus strain, preferably a Lactobacillus crispatus strain deposited under number CNCM I-5579, for reducing pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular for maintaining and / or improving the complexion of healthy skin and / or healthy mucous membranes, preferably for maintaining and / or improving the radiance and / or brightness and / or uniformity of the complexion of healthy skin and / or healthy mucous membranes, and / or for preventing the appearance and / or reducing the presence of pigmented spots, preferably brown spots and / or age spots, on healthy skin and / or healthy mucous membranes, and / or for detoxifying healthy skin and / or healthy mucous membranes, in particular skin of phototypes IV to VI as defined by the Fitzpatrick classification. In the context of the present invention, the Lactobacillus crispatus strain according to the invention is particularly used as a cosmetic and / or nutritional active ingredient.
[0019] According to a particular embodiment of this use, the strain according to the invention reduces and / or inhibits melanogenesis, in particular by acting on the reduction and / or inhibition of melanin, preferably on the reduction and / or inhibition of the synthesis and / or amount of melanin, and / or by reducing and / or inhibiting tyrosinase activity, and / or by detoxifying healthy skin and / or healthy mucous membranes.
[0020] According to one aspect of the present invention, the bacterial strain according to the present invention can be used to maintain and / or improve the skin color of healthy skin and / or healthy mucous membrane. The bacterial strain according to the present invention can also be used to maintain and / or improve the glossiness and / or brightness and / or uniformity of the skin color of healthy skin and / or healthy mucous membrane. The bacterial strain according to the present invention can also be used to prevent the appearance of pigment spots (preferably brown spots and / or senile plaques) of healthy skin and / or healthy mucous membrane and / or reduce its existence. The bacterial strain according to the present invention can also be used to detoxify healthy skin and / or healthy mucous membrane, particularly by antioxidation and / or the effect on lipid peroxidation and / or by the increase and / or stimulation of glutathione synthesis induced by oxidative stress.
[0021] The subject of the present invention is also a cosmetic care method, characterized in that it comprises the topical application of a Lactobacillus crispatus strain according to the invention, preferably the Lactobacillus crispatus CNCM I-5579 strain, or a cosmetic composition comprising this strain, to at least one area of healthy skin and / or healthy mucous membranes for reducing the pigmentation of the skin and / or mucous membranes and / or for preventing its increase, in particular for maintaining and / or improving the skin color of healthy skin and / or healthy mucous membranes, preferably for maintaining and / or improving the gloss and / or brightness and / or uniformity of the skin color of healthy skin and / or healthy mucous membranes, and / or for preventing the appearance of pigmented spots on healthy skin and / or healthy mucous membranes and / or reducing the presence of pigmented spots on healthy skin and / or healthy mucous membranes, and / or for detoxifying the skin and / or mucous membranes. In the context of the present invention, the Lactobacillus crispatus strain according to the invention is particularly used as a cosmetic and / or nutritional active ingredient.
[0022] The subject of the present invention is also a Lactobacillus crispatus strain according to the invention, preferably the Lactobacillus crispatus strain CNCM I-5579, or a pharmaceutical composition, in particular a dermatological composition, comprising this strain, for the prevention and / or treatment of pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmenting pathological skin and / or pathological mucous membranes and / or preventing hyperpigmentation of pathological skin and / or pathological mucous membranes, in order to reduce the pigmentation of the skin and / or mucous membranes and / or prevent its increase, in particular to maintain and / or improve the skin color of pathological skin and / or pathological mucous membranes, preferably to maintain and / or improve the gloss and / or brightness and / or uniformity of the skin color of pathological skin and / or pathological mucous membranes, and / or to prevent the appearance of pigmented spots of pathological skin and / or pathological mucous membranes and / or to reduce the presence of pigmented spots of pathological skin and / or pathological mucous membranes, and / or to detoxify pathological skin and / or pathological mucous membranes. In the context of the present invention, the Lactobacillus crispatus strain according to the invention is used in particular as active ingredient.
[0023] For the purposes of the present invention, the term "cosmetic use" means non-pharmaceutical use, ie pharmaceutical use which is not intended for therapeutic use and which is applied to "healthy" parts of the body, in particular "healthy" areas of the skin and / or mucous membranes.
[0024] For the purposes of the present invention, the expression "nutritional use" means a use intended for non-pharmaceutical oral administration, ie a use which does not require and does not involve a therapeutic treatment.
[0025] The term "skin" means any area of the skin of any part of the body and / or face, including the scalp.
[0026] For the purposes of the present invention, the expression "skin of phototypes IV to VI" is understood to mean a specific skin type classified according to the Fitzpatrick scale (which makes it possible to classify individuals according to the reaction of their skin and hair during exposure to UV rays) and / or as so classified by dermatologists according to the color of the skin (which depends in particular on the activity level of melanocytes, the production of these cells and their grouping). Preferably, these dark skins of phototypes IV to VI originate from a characteristic ethnic origin, respectively from India, Asia and / or Africa. In particular,
[0027] - Phototype IV (Mediterranean) corresponds to light matte skin and brown or black hair and brown or dark eyes. Rarely sunburns, skin tans easily, dark brown;
[0028] - Light type V (Latin type) corresponds to light matte skin, black hair and dark eyes. Rarely sunburns, skin tans easily and is dark brown;
[0029] - Phototype VI (Afro) corresponds to very dark skin, dark hair, and dark eyes. Sunburn is very rare.
[0030] According to the present invention, "mucosa" means ocular mucosa, nasal mucosa, ear mucosa, vaginal mucosa, urogenital mucosa and / or oral mucosa, in particular oral mucosa, labial mucosa and / or gingival mucosa, preferably ocular mucosa and / or oral mucosa, more preferably labial mucosa and / or ocular mucosa. Advantageously, the term does not include vaginal mucosa.
[0031] For the purposes of the present invention, the term "healthy skin" or "healthy mucosa" means an area of skin or mucosa to which the strain of the invention is applied and which is referred to by dermatologists as "non-pathological", i.e. free of infection, scarring, disease, inflammation or skin disorders such as candidiasis, impetigo, psoriasis, eczema, acne or dermatitis, or wounds or injuries.
[0032] For the purposes of the present invention, the term "Lactobacillus crispatus strain" is understood to mean the bacterium Lactobacillus crispatus in whole form or in part form, in particular in the form of a lysate, in the form of a fraction or in the form of a metabolite. Advantageously, the Lactobacillus crispatus strain is not genetically modified.
[0033] The Lactobacillus crispatus strain according to the invention may be derived from any known Lactobacillus crispatus species. Preferably, the Lactobacillus crispatus strain is the species deposited under the Budapest Treaty on September 9, 2020 at the Pasteur Institute (28, rue Dr. Roux, Paris 15, F-75024) under the name CNCM I-5579.
[0034] The advantage of this particular strain of Lactobacillus crispatus is that it is the first Lactobacillus crispatus to be found naturally on the skin.
[0035] For the purposes of the present invention, the expression "reducing pigmentation of the skin and / or mucous membranes and / or preventing its increase" is to be understood as meaning depigmenting, whitening, brightening the skin and / or mucous membranes, preventing an increase in the skin color and / or tone of the skin and / or mucous membranes, maintaining and / or preserving and / or improving the skin color and / or tone of the skin and / or mucous membranes, and preferably reducing and / or preventing an increase in their melanin production, and more preferably reducing and / or inhibiting, in whole or in part, gene and / or protein expression and / or tyrosinase activity and / or reducing and / or inhibiting the synthesis and / or amount of melanin.
[0036] The pigmentation process of the skin is also called "melanogenesis" and includes many steps ranging from the synthesis of melanin in melanocytes to its transport into the keratinocytes of the epidermis with the help of melanosomes. Several proteins are involved in this process. Tyrosinase is an enzyme involved in the key step of melanin synthesis; it collaborates with other proteins to convert melanin into eumelanin and pheomelanin, which are the melanins responsible for the pigmentation process.
[0037] The expression "reduce and / or inhibit melanin production" is understood to mean total or partial reduction and / or inhibition of gene and / or protein expression and / or tyrosinase activity and / or total or partial reduction and / or inhibition of the synthesis and / or amount of melanin.
[0038] According to the invention, the expression "totally or partially reduces and / or inhibits tyrosinase activity" is understood to mean that in the presence of the Lactobacillus crispatus strain according to the invention, the tyrosinase activity is reduced by at least 25%, preferably at least 50%, more preferably at least 75% relative to the activity level measured in the absence of the extract.
[0039] Preferably, the tyrosinase activity is measured on tyrosinase extracted from "normal" human melanocytes, more preferably the tyrosinase activity is measured by measuring the production of melanin by photometric measurement of the absorbance at 540 nm of tyrosinase extracted from "normal" human melanocytes, more preferably in the presence of a Lactobacillus crispatus strain prepared according to Example 1.e, advantageously under the conditions described in Example 3.
[0040] According to the present invention, the expression "total or partial reduction and / or inhibition of the synthesis and / or amount of melanin" means that the synthesis and / or amount of melanin in the presence of the strain is reduced by at least 10%, preferably at least 20%, more preferably at least 30% of melanin relative to the synthesis and / or amount of melanin detected in the absence of the Lactobacillus crispatus strain according to the present invention. In a preferred embodiment of the present invention, what is discussed is the reduction in the amount of melanin in the presence of the Lactobacillus crispatus strain according to the present invention prepared according to Example 1.a or according to Example 1.e. More preferably, the amount of melanin is measured by optical density at 475 nm using B16 melanocytes cultured in vitro in a medium comprising fetal bovine serum, advantageously under the conditions described in Example 2. In another preferred embodiment, the amount of melanin is measured by using the optical density at 475 nm of a co-culture of "normal" human melanocytes and keratinocytes, which is advantageously cultured in vitro in a medium comprising growth factors under the conditions described in Example 4.
[0041] For the purposes of the present invention, the expression "maintaining and / or improving skin color" is to be understood as meaning maintaining the glossiness and / or brightness and / or radiance and / or lightness and / or uniformity of the skin color and / or preventing a reduction in the glossiness and / or brightness and / or radiance and / or lightness and / or uniformity of the skin color and / or increasing the glossiness and / or brightness and / or radiance and / or lightness and / or uniformity of the skin color and / or reducing and / or reducing dullness and / or earthy skin tone of the skin and / or mucous membranes.
[0042] The measurement of the glossiness, brightness and uniformity of the skin and / or mucous membrane complexion can be studied by measurement techniques known to those skilled in the art, and in particular these measurements can be carried out, for example, in vivo by colorimetry or by image analysis. The latter in vivo measurement method consists in taking high-resolution photographs (taken at 45°) of the face of a volunteer in a cross-polarization configuration before and after the application of the test product. Based on these digital photographs, image analysis enables the extraction and quantification of specific parameters related to the color, glossiness and uniformity of the skin (e.g. L*, a*, b*, C, h°).
[0043] For the purposes of the present invention, the expression "maintaining and / or improving the radiance of the skin tone" is to be understood as meaning maintaining the brightness and / or radiance and / or lightness and / or clarity of the mucous membranes and / or preventing a reduction in the brightness and / or radiance and / or lightness and / or clarity of the mucous membranes and / or increasing the brightness and / or radiance and / or lightness and / or clarity of the skin and / or mucous membranes and / or reducing and / or reducing the dullness and / or earthy skin tone of the skin and / or mucous membranes.
[0044] For the purposes of the present invention, the expression "maintaining and / or improving the evenness of skin color" is to be understood as meaning maintaining the amount and / or extent of imperfections and / or irregularities in the color of the skin color and / or preventing an increase in the amount and / or reducing the amount and / or extent of imperfections and / or irregularities in the color of the skin color, in particular selected from redness, pigmentation spots, pimples, freckles and / or visible pores.
[0045] The measurement of the uniformity of the skin complexion and the amount of melanin in the skin can be performed by skin pigmentation measurement (mexametry). This in vivo measurement method consists in using the absorption / reflection principle to deduce therefrom the melanin index which reflects the amount of melanin present in the skin.
[0046] Advantageously, under the conditions described in Example 7, the improvement in skin color is measured in a population of women with facial pigmented spots, preferably by applying a cream containing a Lactobacillus crispatus strain prepared according to Example 1.e.
[0047] The expression "maintaining blemishes and / or irregularities in the color of the skin color and / or preventing an increase in blemishes and / or irregularities in the color of the skin color and / or reducing blemishes and / or irregularities in the color of the skin color" is to be understood as meaning that during 28 days of application to the skin, in the presence of the strain according to the invention, an increase in the amount of melanin in the skin is prevented by at least 2%, advantageously at least 3%, and / or the amount of melanin in the skin is reduced by at least 2%, advantageously at least 3%, relative to the amount of melanin detected in the absence of the strain; and / or, during 56 days of application to the skin, in the presence of the strain according to the invention, an increase in the amount of melanin in the skin is prevented by at least 2%, advantageously at least 5%, and / or the amount of melanin in the skin is reduced by at least 2%, advantageously at least 5%, relative to the amount of melanin detected in the absence of the strain.
[0048] The expression "preventing the appearance of pigmented spots and / or reducing the presence of pigmented spots" is to be understood as meaning maintaining the pigmentation of local pigmented spots and / or preventing an increase in the pigmentation of local pigmented spots and / or reducing the pigmentation of local pigmented spots, in particular pigmented spots typically on the face, neckline, neck, back, shoulders and / or hands, especially the number and / or intensity of spots on the back of the hands.
[0049] Pigmented spots are particularly brown and / or dark and / or white spots and / or "age spots" when they are located on parts of the body exposed to UV radiation and / or are associated with age-related or UV-induced senescence, for example during exposure to sunlight. Pigmented spots also include freckles and / or moles and / or post-inflammatory spots and / or spots that appear in response to an attack, and / or spots of hormonal origin (especially in the case of melasma or melasma (also known as pregnancy spots)), and / or drug-induced spots, and / or for preventing and / or combating unsightly pigmentary manifestations of the skin and / or mucous membranes associated with non-skin pathological conditions.
[0050] The Applicant has also discovered that a strain of Lactobacillus crispatus, in particular the strain deposited under the name CNCM 1-5579, can be used to detoxify the skin and / or mucous membranes, in particular healthy skin and / or healthy mucous membranes.
[0051] The term "detoxification of the skin and / or mucous membranes" is understood to mean the prevention and / or complete and / or partial inhibition of oxidative stress, in particular by preventing and / or complete and / or partial inhibition of the formation of free radicals and / or the formation of lipid peroxidation and / or by increasing and / or stimulating the synthesis of glutathione which has antioxidant and detoxifying properties.
[0052] Detoxification makes it possible to protect the skin from both external and internal aggressions causing oxidative stress that could tend to impair its proper functioning and to adversely modify its appearance, and in particular means capable of stimulating the natural systems of protection and repair of the skin cells and limiting the induction of cellular damage.
[0053] The term "oxidative stress" refers to the formation of excess reactive species, including reactive oxygen species and reactive nitrogen species, which form when the skin is subjected to oxidative stress caused by various factors such as solar ultraviolet, infrared and visible light, environmental pollution (including ozone and particulates), and psychological stress.
[0054] In addition to affecting the effectiveness of the skin's detoxification systems, oxidative stress can also exacerbate pigmentation, particularly by inducing skin color irregularities or pigmentary disorders.
[0055] In a preferred embodiment of the present invention, what is discussed is the reduction and / or inhibition of the formation of DPPH° (2,2-diphenyl-1-picrylhydrazyl) radicals by at least 10%, preferably at least 30%, in the presence of a Lactobacillus crispatus strain according to the present invention, relative to the formation of DPPH° radicals detected in the absence of this strain, and / or the reduction and / or inhibition of the release of intracellular free radicals induced by oxidative stress (preferably UVA rays) by at least 20%, preferably at least 50%, in the presence of a Lactobacillus crispatus strain according to the present invention, relative to the release of intracellular free radicals detected in the absence of this strain.
[0056] In a preferred embodiment of the present invention, it is discussed that the spontaneous formation of DPPH° radicals is reduced and / or inhibited in the presence of a Lactobacillus crispatus strain according to the present invention prepared according to examples 1.a and / or 1.e.
[0057] More preferably, the formation of DPPH° radicals is measured in the tube by optical density at 530 nm under the conditions described in Example 5.a.
[0058] In a preferred embodiment of the present invention, it is discussed that the release of intracellular free radicals induced by oxidative stress, preferably by UVA rays, is reduced and / or inhibited in the presence of a Lactobacillus crispatus strain according to the present invention prepared according to example 1.a.
[0059] More preferably, under the conditions described in Example 5.b, the release of intracellular free radicals induced by oxidative stress (preferably UVA rays) is measured by the fluorescence emitted by the formation of DCF (2′, 7-dichlorofluorescein) by a DCFH-DA (2′, 7′-dichlorodihydrofluorescein diacetate) probe from normal human fibroblasts at an excitation wavelength of 485 nm and an emission wavelength of 538 nm.
[0060] In another embodiment, what is discussed is "preventing and / or inhibiting peroxidation of membrane lipids", that is to say preventing and / or completely or partially inhibiting lipid oxidation induced by oxidative stress (preferably UVA rays) by at least 10%, preferably at least 30%, in the presence of the strain, compared to the lipid peroxidation detected in the absence of the Lactobacillus crispatus strain according to the invention.
[0061] In a preferred embodiment of the present invention, it is discussed that peroxidation of membrane lipids induced by oxidative stress, preferably UVA rays, is prevented and / or inhibited in the presence of a Lactobacillus crispatus strain according to the present invention prepared according to example 1.a.
[0062] More preferably, peroxidation of membrane lipids induced by oxidative stress (preferably UVA rays) is measured by fluorescence formed by malondialdehyde (MDA) from normal human fibroblasts at an excitation wavelength of 532 nm and an emission wavelength of 560 nm under the conditions described in Example 5.c.
[0063] According to another embodiment, what is in question is the maintenance and / or stimulation of glutathione synthesis, that is to say the prevention of a decrease in the expression and / or amount of glutathione by at least 20%, preferably at least 50%, and / or the increase of the expression and / or amount of glutathione by at least 20%, preferably at least 50%, in the presence of the Lactobacillus crispatus strain according to the invention, in the presence of this strain, in the presence of oxidative stress, preferably induced by UVA rays.
[0064] In a preferred embodiment of the present invention, it is discussed that the synthesis of glutathione induced by oxidative stress, preferably UVA rays, is maintained and / or stimulated in the presence of a Lactobacillus crispatus strain according to the present invention prepared according to example 1.a.
[0065] More preferably, glutathione synthesis is measured in vitro under the conditions described in Example 6 by fluorescence from normal human fibroblasts at an excitation wavelength of 355 nm and an emission wavelength of 430 nm.
[0066] According to the invention, the Lactobacillus crispatus strain can be used in intact form, in particular alive and / or inactivated, in particular dead, and / or in the form of a lysate, and / or in the form of one or more fractions thereof, and / or in the form of one or more of its metabolites, preferably its secretome.
[0067] For each of its forms, the strain according to the invention can be isolated or combined with its culture medium.
[0068] Preferably, the strain according to the invention is used in combination with its culture medium, that is to say is contained in its culture medium.
[0069] For the purposes of the present invention, the term "culture medium" is understood to mean a support containing nutrient elements capable of culturing and / or proliferating the Lactobacillus crispatus strain according to the invention. Preferably, the culture medium is MRS (Man, Rogosa and Sharp agar) medium.
[0070] For the purposes of the present invention, the term "isolated" means that it is not mixed with one or more compounds with which it may be associated in its culture medium.
[0071] For the purposes of the present invention, the term "intact form" means its natural form, ie a form in which the bacterial envelope is intact, rather than a lysed form. When used in intact form, the Lactobacillus crispatus strain may be alive and / or inactivated and / or dead.
[0072] For the purposes of the present invention, the term "viable" refers to a Lactobacillus crispatus strain according to the present invention that is capable of forming colonies in culture.
[0073] The production of the Lactobacillus crispatus strain in live, intact form can be carried out according to any method conventionally known to the person skilled in the art. Advantageously, it will be carried out according to the protocol described, for example, in Example 1.a.
[0074] For the purposes of the present invention, the term "inactivated" refers to a Lactobacillus crispatus strain according to the invention which is no longer able to transiently or definitively form colonies in culture.
[0075] The inactivation of the Lactobacillus crispatus strain can be carried out by any method conventionally known to the skilled person. It can be inactivated in particular by irradiation, heat treatment or under certain conditions by high pressure treatment or by extrusion, advantageously it will be carried out by heat treatment, more advantageously according to the protocol described in example 1.b for example.
[0076] Heat inactivation can be performed by incubating the Lactobacillus crispatus strain at a temperature advantageously from about 60°C to 150°C for a given period of time, advantageously about 10s to 90min, preferably about 15 minutes to one hour. Preferably, it is incubated at about 80°C for about 30 minutes.
[0077] For the purposes of the present invention, the term "dead" refers to a Lactobacillus crispatus strain according to the present invention which is no longer able to definitively form colonies in culture.
[0078] For the purposes of the present invention, the term "lysate" means a substance obtained after the destruction or dissolution of biological cells by a phenomenon known as cell lysis, resulting in the release of fragments of intracellular biological components and cell membrane components naturally contained in the cells of the microorganism in question. The lysate used is therefore formed by all the intracellular biological components and the components of the cell wall and cell membrane of the Lactobacillus crispatus strain according to the invention.
[0079] The lysate can be obtained by any method conventionally known to those skilled in the art. It can be obtained in particular by osmotic shock, thermal shock, by ultrasound, by enzymatic cleavage, by crystallization or under mechanical stress of the centrifugal type, or by increasing the pressure or a combination of these different techniques.
[0080] Preferably, the lysate will be obtained by a combination of mechanical action and pressure increase. More preferably, the lysate will be obtained according to a protocol as described for example in Example 1.c.
[0081] In a preferred embodiment of the invention, the lysate will be combined with bacterial culture medium.
[0082] Preferably, the lysate obtained does not contain any active enzyme, in particular active sphingomyelinase.
[0083] For the purposes of the present invention, the term "fraction" is understood to mean a fragment of the Lactobacillus crispatus strain according to the invention, which is effective in reducing the pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular for maintaining and / or improving the skin color of the skin and / or mucous membranes, preferably for maintaining and / or improving the glossiness and / or brightness and / or uniformity of the skin color of the skin and / or mucous membranes, and / or for preventing the appearance of pigmented spots on the skin and / or mucous membranes and / or reducing the presence of pigmented spots on the skin and / or mucous membranes and / or detoxifying the skin and / or mucous membranes. This fraction corresponds to a non-total part of the intracellular biological components and the cell wall and membrane components obtained by lysing the Lactobacillus crispatus strain according to the invention.
[0084] According to a particular embodiment of the invention, these fractions may be bacterial protoplasm. According to a particular embodiment of the invention, this fraction corresponds to all intracellular biological components, but without the components of the cell wall and cell membrane of the Lactobacillus crispatus strain.
[0085] According to a particular embodiment of the invention, the obtained fraction does not contain any active enzyme, in particular active sphingomyelinase.
[0086] In a preferred embodiment of the invention, this fraction will be combined with bacterial culture medium.
[0087] For the purposes of the present invention, the term "metabolite" is understood to mean one or more organic and / or inorganic molecules derived from the metabolism of the Lactobacillus crispatus strain according to the invention and which are also effective in reducing the pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular for maintaining and / or improving the skin color of the skin and / or mucous membranes, preferably for maintaining and / or improving the glossiness and / or brightness and / or uniformity of the skin color of the skin and / or mucous membranes, and / or for preventing the appearance of pigmented spots on the skin and / or mucous membranes and / or reducing the presence of pigmented spots on the skin and / or mucous membranes and / or detoxifying the skin and / or mucous membranes. Preferably, this is the secretome of the Lactobacillus crispatus strain according to the invention.
[0088] In certain embodiments of the invention, the metabolites will be combined with the bacterial culture medium.
[0089] For the purposes of the present invention, the term "secretome" is understood to mean all organic and / or inorganic molecules secreted by the Lactobacillus crispatus strain according to the invention, which are effective in reducing pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular for maintaining and / or improving the skin color of the skin and / or mucous membranes, preferably for maintaining and / or improving the gloss and / or brightness and / or uniformity of the skin color of the skin and / or mucous membranes, and / or for preventing the appearance of pigmented spots on the skin and / or mucous membranes and / or reducing the presence of pigmented spots on the skin and / or mucous membranes and / or detoxifying the skin and / or mucous membranes.
[0090] The secretome can be obtained by any method conventionally known to the person skilled in the art. Advantageously, it will be obtained according to a protocol as described, for example, in Example 1.e.
[0091] In a preferred embodiment of the invention, the secretome will be combined with the bacterial culture medium.
[0092] According to a specific embodiment of the invention, the metabolites and / or the secretome do not contain active enzymes, in particular active sphingomyelinase.
[0093] According to a preferred embodiment of the present invention, the Lactobacillus crispatus strain according to the present invention will be used in live intact form and / or in the form of one or more of its metabolites, preferably in the form of its secretome.
[0094] Preferably, the Lactobacillus crispatus strain according to the invention will be used in an effective amount for reducing the pigmentation of the skin and / or mucous membranes and / or preventing an increase in the pigmentation of the skin and / or mucous membranes.
[0095] According to an advantageous embodiment, the Lactobacillus crispatus strain according to the invention does not contain sphingomyelinase.
[0096] According to an advantageous embodiment of the invention, the Lactobacillus crispatus strain according to the invention is topically applied to healthy skin and / or healthy mucous membranes. Preferably, the skin and / or mucous membranes are phototypes IV to VI. Phototypes IV to VI are as defined by the Fitzpatrick classification.
[0097] For the purposes of the present invention, the term "topical route" means direct topical application and / or spraying of the Lactobacillus crispatus strain according to the invention or a composition comprising the strain according to the invention onto the surface of the skin and / or mucosal area of concern.
[0098] According to the invention, the Lactobacillus crispatus strain according to the invention can be used alone in the form of an active ingredient and / or in a cosmetic and / or nutritional and / or pharmaceutical composition, in particular a dermatological composition, preferably intended for topical and / or oral application, more preferably for topical application.
[0099] When it is used in a living whole form according to the invention, and when it is used alone in the form of an active ingredient, the strain according to the invention can be in dry form, i.e. in the form of a powder, advantageously in maltodextrin, preferably with a strain content of 10% to 80% (w / w) by weight of the strain, preferably 30% to 70% (w / w) by weight of the strain, more advantageously 40% to 60% (w / w) by weight of the strain, relative to the total weight of the powder.
[0100] Alternatively, the active intact form according to the invention can be dispersed and / or diluted in a solvent for use. Preferably, the solvent contains less than 20% (v / v) water by volume, more preferably less than 5% (v / v) water by volume; more preferably, the solvent does not contain any water.
[0101] According to an alternative embodiment, the solvent contains less than 20% by weight (w / w) water, more preferably less than 5% by weight (w / w) water, more preferably the solvent contains no water. Very preferably, the solvent is a cosmetically acceptable oil.
[0102] When it is used in its entire inactivated form (in particular dead), and / or in the form of a lysate, and / or in the form of one or more of its fractions, and / or in the form of one or more of its metabolites (in particular its secreted proteome), and when it is used alone in the form of an active ingredient, the strain according to the invention can be in dry form, i.e. in the form of a powder, advantageously in maltodextrin, preferably with a strain content of: 1% to 80% (w / w) by weight of the strain, preferably 3% to 50% (w / w) by weight of the strain, very preferably about 5% or 20% (w / w) by weight of the strain relative to the total weight of the powder, more preferably about 10% (w / w), more preferably 10% (w / w) by weight of the strain relative to the total weight of the powder.
[0103] Alternatively, the inactivated intact form, in particular the dead form, and / or the lysate, and / or the fraction, and / or the metabolite, in particular the secretome according to the invention, can be used dissolved and / or diluted and / or dispersed in a solvent, in particular a polar solvent, such as water, an alcohol, a polyol, a glycol such as pentanediol and / or hexanediol and / or caprylyl glycol and / or butanediol or a mixture thereof, preferably a water-glycol or a water-alcohol mixture, more preferably comprising a glycol selected from hexanediol, caprylyl glycol and a mixture thereof.
[0104] In another embodiment, the strain according to the invention may be incorporated into a cosmetic and / or nutritional composition comprising at least one cosmetically acceptable and / or nutritionally acceptable excipient. Preferably, it is incorporated into a cosmetic composition comprising at least one cosmetically acceptable excipient.
[0105] For the purposes of the present invention, the term "cosmetically acceptable" excipients means topically acceptable compounds and / or solvents, i.e. compounds and / or solvents that do not cause allergic reactions when in contact with the skin (including the human scalp) and / or mucous membranes and are non-toxic and chemically stable.
[0106] In a preferred embodiment, the strain according to the invention will be incorporated into a cosmetic composition alone, that is, it will not be used to ferment a plant extract. In other words, a cosmetic composition comprising the strain according to the invention does not contain any plant extract fermentation of the strain.
[0107] In a preferred embodiment of the present invention, the strain according to the present invention is used in an effective amount, i.e., 1×10 by weight relative to the total weight of the composition. -4 % to 10% (w / w), preferably between 1×10 -4 % and 5% (w / w), more preferably between 1×10 -3 % and 0.5% (w / w) are present in a cosmetic composition further comprising at least one cosmetically acceptable excipient.
[0108] In a particularly advantageous manner, when the strain according to the invention is used in the form of one or more of its metabolites, in particular its secretome, it is present in a cosmetic composition further comprising at least one cosmetically acceptable excipient in an effective amount for reducing pigmentation of the skin and / or mucous membranes and / or preventing an increase in pigmentation of the skin and / or mucous membranes, i.e. in a concentration of 0.05% to 0.5% (w / w) by weight, more preferably in a concentration of about 0.1% (w / w) by weight, relative to the total weight of the composition.
[0109] Particularly advantageously, when the strain according to the invention is used in live intact form, it is present in a cosmetic composition further comprising at least one cosmetically acceptable excipient in an effective amount for reducing the pigmentation of the skin and / or mucous membranes and / or preventing an increase in the pigmentation of the skin and / or mucous membranes, i.e. in a concentration ranging from 0.01% to 0.1% (w / w) by weight, more preferably in a concentration of about 0.025% (w / w) by weight, relative to the total weight of the composition.
[0110] The cosmetic composition according to the invention may be chosen from aqueous or oily suspensions or solutions, creams or aqueous or oily gels, in particular shower gels, shampoos; milks; emulsions, microemulsions or nanoemulsions, in particular oil-in-water or water-in-oil or multi- or silicone-based emulsions; masks; serums; lotions; liquid soaps; emollient cleansing soaps; ointments; balms; butters; mousses; patches; anhydrous products, which are preferably liquid, paste or solid, for example in the form of cosmetic powders, sticks or sticks, in particular in the form of lipsticks.
[0111] It can also be a makeup product or a makeup remover.
[0112] Advantageously, the Lactobacillus crispatus strain or composition of the invention is intended to be applied to healthy skin and / or healthy mucous membranes of all or part of the body and / or face and / or scalp, preferably to the legs, thighs, arms, abdomen, neckline, neck, armpits or lips, more preferably to all or part of the face, and preferably to the cheeks, forehead, chin, lips or around the eyes.
[0113] Advantageously, the strain and / or the composition comprising the strain is intended to be applied to areas of healthy skin showing a dull complexion and / or areas of non-uniform healthy skin and / or areas of healthy skin showing pigmented spots.
[0114] Preferably, the Lactobacillus crispatus strain according to the invention is particularly suitable for formulating neutral and mild compositions for use on the sebaceous glands, in particular the skin and / or mucous membranes including the scalp.
[0115] Alternatively, the Lactobacillus crispatus strain according to the invention may be in any presentation form conventionally used for oral application, in particular in the form of a nutritionally active ingredient and / or a nutritional composition.
[0116] The composition according to the invention may contain any suitable solvent and / or any suitable vehicle and / or any suitable excipient, optionally in combination with other compounds of interest.
[0117] Thus, for these compositions, the excipient contains, for example, at least one compound selected from the group comprising preservatives, emollients, emulsifiers, surfactants, humectants, thickeners, conditioners, matting agents, stabilizers, antioxidants, texturizing agents, glossing agents, film formers, solubilizers, pigments, dyes, fragrances and sunscreens. These excipients are preferably selected from the group consisting of amino acids and their derivatives, polyglycerols, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrin, lactoperoxidase, sucrose-based stabilizers, vitamin E and its derivatives, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, vegetable esters, silicones and their derivatives, protein hydrolysates, jojoba oil and its derivatives, fat-soluble / water-soluble esters, betaine, amine oxides, plant extracts, sucrose esters, titanium dioxide, glycine and parabens, and more preferably selected from the group consisting of butylene glycol, steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben, butylene glycol, natural tocopherols. Phenol, glycerin, sodium dihydroxycetyl phosphate, isopropyl hydroxycetyl ether, glycol stearate, triisononanoin, octyl cocoate, polyacrylamide, isoparaffin, laureth-7, carbomer, propylene glycol, glycerin, bisabolol, dimethicone, sodium hydroxide, PEG-30-dipolyhydroxystearate, capric / caprylic triglyceride, caprylic cetearyl, dibutyl adipate, grape seed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum, citric acid, sodium lauryl sulfate, mineral waxes and oils, isostearyl isostearate, propylene glycol dipelargonate, propylene glycol isostearate, PEG8, beeswax, glycerides from hydrogenated palm kernel oil, glycerides from hydrogenated palm oil, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose, low density polyethylene, isotonic saline solution, and mixtures thereof.
[0118] Many cosmetic active ingredients are known to those skilled in the art for improving the health and / or physical appearance of the skin (including the scalp) and / or mucous membranes. Those skilled in the art know how to formulate cosmetic, nutritional or dermatological compositions to achieve optimal results. In addition, these compounds may have synergistic effects when combined with each other. These combinations are also encompassed by the present invention. The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a variety of cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industries that are particularly suitable for topical use. Examples of these categories of ingredients include, but are not limited to, the following compounds: abrasives, absorbents, compounds for aesthetic purposes (e.g., fragrances, pigments, dyes, essential oils), astringents and the like (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel extract), anti-acne agents, anti-flocculating agents, defoaming agents, antimicrobial agents (e.g., iodopropyl butyl carbamate), antioxidants, adhesives, biological additives, buffers, bulking agents, chelating agents, additives, biocides, denaturants, thickeners, and vitamins and their derivatives or equivalents, film-forming materials, polymers, sunscreens, pH adjusters, reducing agents, decolorizing or brightening agents (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, glucosamine ascorbic acid), conditioning agents (e.g., wetting agents).
[0119] The cosmetic composition may also comprise other cosmetic and / or nutritional agents having the same properties as the Lactobacillus crispatus strain according to the invention and inducing a synergistic or non-synergistic effect, or cosmetic agents having a complementary effect.
[0120] They may be, for example, depigmenting and / or lightening ingredients and / or ingredients intended to reduce pigmented spots on the skin, such as niacinamide or vitamin B3, arbutin, azelaic acid, ascorbic acid or derivatives thereof, marketed by BASF Beauty Care Solutions France under the name Dermawhite TM WF sells a combination of extracts of the plants Saxifraga sarmentosa, Psidium guajava, and Carica papaya under the name Phytolight TM BG sells a combination of sulfites and extracts of tea tree (Camellia sinensis), skullcap (Scutellaria baicalensis), cucumber (Cucumis sativus), and apple (Pyrus malus) under the name DN-Aura TMA standardized extract of Lansium domesticum leaf is sold under the name Actiwhite TM A combination of pea extract and sucrose dilaurate, a derivative of 4-hydroxyphenoxyacetic acid, is sold, in particular, by BASF Beauty Care Solutions France under the name Radianskin TM 2-(4-Hydroxyphenoxy)propionic acid, or Hyalurosmooth TM A purified polysaccharide extract from the seeds of Cassia angustifolia is sold under the name X-Pressin TM A stabilized protease extract isolated from the latex of Carica papaya is sold under the name Cytovector ferulic TM Cationic liposomes encapsulating ferulic acid are sold or marketed by BASF Beauty Care Solutions France under the name AH-Care TM A complex of glycolic acid and L-arginine for sale.
[0121] Among other active ingredients that can be combined with the strains according to the invention, in question may be plant extracts having similar properties of preventing the appearance of pigmentation and / or increasing the radiance of the complexion, in particular those marketed by the Applicant under the name Inolixir TM The extract of the fungus Chaga (Inonotus obliquus) is sold by the applicant under the name Arganyl TM The extract of Argania spinosa oil is sold by the applicant under the name Purisoft TM The extract of Moringa oleifera seeds sold by the applicant under the name CollRepair TM The combination of Salviamiltiorrhiza extract and niacinamide sold by the applicant under the name NeurobiOx TM Extract of yarrow (Achillea millefolium) sold under the name DN-age TM Extract of Cassia alata leaves sold under the name Litchiderm TM The extract of lychee is sold as an antioxidant active agent, and is marketed by the applicant under the name Lox-Age TM Chicory extract is sold under the name Vitacell TM Yeast extract sold under the name Perlaura TMExtract of Polygonum bistorta sold under the name Hyalufix TM Galanga extract sold under the name Deliner TM Corn extract sold under the name Epigenist TM Extracts of Voandzeia subterranea, or active agents promoting skin firming, sold by the applicant under the name Dermican TM A synthetic tetrapeptide sold under the name Linefactor TM Extracts of Hibiscus abelmoschus are sold under the name Proteasyl TM A purified extract of pea sold under the name Elestan TM Extracts of the Malachitia tree (Manilkara multinervis) are sold. They can also be sold under the name Dermagenist TM Extracts of the plant Origanum majorana sold under the name Extracts of African neem (Khayasenegalensis) sold under the name Eperulin TM Extracts of Eperua falcata or containing phytosterols (particularly, derived from rapeseed oil and marketed by the applicant under the name Phytosoothe TM The extracts of β-sitosterol and / or campesterol and / or brassicasterol sold as Benzosterol are added to the cosmetic composition.
[0122] They can also be anti-aging active ingredients and / or tonicity agents for a synergistic effect with the Lactobacillus crispatus strains. Advantageously, they are active ingredients that increase the gene and / or protein expression of collagen or that prevent collagen degradation, such as retinol, vitamin C, TM The extract of Davilla rugosa sold by the applicant under the name Linefactor TM Hibiscus abelmoschus seed extract is sold under the name Phytokine TM Soy protein hydrolysate extract sold under the name Dermican TM The peptide is sold by Sederma under the name Matrixyl TM 、Matrixyl 3000 TMand Regestril TM or Neuroguard from Codif, or Eternaline from Silab TM Products for sale.
[0123] The tonicity agents useful in the present invention may be chosen from synthetic polymers such as polyurethane latex or acrylic latex, polymers of natural origin, in particular polysaccharides in the form of starch or carrageenan, alginates, agar, gellan gum, cellulose-based polymers and pectin; vegetable proteins and protein hydrolysates; mixed silicates; wax microparticles; colloidal particles of inorganic fillers selected from, for example, silica, silica-alumina composites; and mixtures thereof.
[0124] Advantageously, the Lactobacillus crispatus strain according to the invention may be combined with a cosmetic agent selected from benzoic acid and / or its salts, levulinic acid and / or its salts (eg sodium levulinate), sorbic acid and / or its salts, anisic acid and / or its salts, and mixtures thereof.
[0125] Finally, they may be cosmetic ingredients, such as antimicrobial agents, free radical scavengers, soothing agents, tranquilizers or relaxants, agents acting on microcirculation to improve complexion, especially facial radiance, healing agents or slimming agents. Advantageously, the cosmetic and / or dermatological composition according to the invention also contains one or more tonicity agents and / or one or more antimicrobial agents and / or one or more free radical scavengers and / or one or more soothing agents and / or one or more slimming agents and / or one or more agents acting on microcirculation.
[0126] Among the antimicrobial agents with which the Lactobacillus crispatus strain is combined in a preferred embodiment of the invention in a non-viable form, mention may be made of 2,4,4′-trichloro-2′-hydroxydiphenyl ether (or triclosan), 3,4,4′-trichloroaniline, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, hexamidine isethionate, metronidazole and its salts, miconazole and its salts, itraconazole, terconazole, econazole, ketoconazole, saperconazole, fluconazole, clotrimazole, butoconazole, oxiconazole, sulfaconazole, sulconazole, terbinafine, undecylenic acid and its salts, benzoyl peroxide, 3-hydroxybenzoic acid, 4-hydroxybenzoic acid, phytic acid, N-acetyl-L-cysteine, lipoic acid, azelaic acid and its salts, arachidonic acid, resorcinol, octoxyglycerol, caprylyl glycine, caprylyl glycol, 10-hydroxy-2-decanoic acid, farnesol, phytosphingosine and mixtures thereof.
[0127] The free radical scavenger can be vitamin C and its derivatives, including ascorbyl glucoside, phenols and polyphenols, especially tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it, especially green tea extract; anthocyanins; phenolic acids, stilbenes; monocyclic or polycyclic aromatic compound scavengers, tannins such as ellagic acid and indole derivatives and / or heavy metal scavengers such as EDTA, free radical scavengers such as vitamin E and its derivatives such as tocopherol acetate; bioflavonoids; coenzyme Q10 or ubiquinone.
[0128] As soothing agents included in the composition of the invention, use may be made of pentacyclic triterpenes, ursolic acid and its salts, oleanolic acid and its salts, betulinic acid and its salts, salicylates (and especially zinc salicylate), bisabolol, allantoin, omega-3 unsaturated oils, cortisone, hydrocortisone, indomethacin and betamethasone, anti-inflammatory active agents, and in particular those described in patent application FR 2 847 267, in particular by the applicant under the name Inhipase TM Pueraria lobata root extract, and Theobroma cacao extract are marketed.
[0129] The active ingredients acting on the microcirculation, vasoprotectants or vasodilators may be selected from flavonoids, ruscosapogenins, nicotinates and essential oils.
[0130] The slimming active agent may be chosen in particular from lipoprotein lipase inhibitors, such as those described in patent US 2003086949 (Coletica Skin Research Center) and in particular extracts of the Peruvian vine (Uncariatomentosa); drainage active agents, in particular hesperidin laurate (Flavagrum TM ) or quercetin octanoate (Flavenger TM ); phosphodiesterase inhibitors, adenylate cyclase activators, cAMP and / or agents capable of capturing spermine and / or spermidine. Examples include Coleus Forskohlii root extract, Cecropia obtusa extract, Uva lactuca extract, caffeine, forskolin, theophylline, theobromine and / or their derivatives, a product sold by the applicant called Slimexcess TM Hydrolyzed K carrageenan products and / or mixtures thereof.
[0131] The subject of the present invention is also a cosmetic care method, which comprises the topical application of a Lactobacillus crispatus strain according to the invention or a cosmetic composition comprising this strain to at least one area of healthy skin and / or healthy mucous membranes, for reducing the pigmentation of the skin and / or mucous membranes and / or for preventing its increase, in particular for maintaining and / or improving the skin color of healthy skin and / or healthy mucous membranes, preferably for maintaining and / or improving the gloss and / or brightness and / or evenness of the skin color of healthy skin and / or healthy mucous membranes, and / or for preventing the appearance and / or reducing the presence of pigmented spots on healthy skin and / or healthy mucous membranes, and / or for detoxifying the skin and / or mucous membranes.
[0132] Advantageously, the Lactobacillus crispatus strain according to the invention is used for regular topical application, preferably in the form of a cosmetic composition according to the invention, and preferably at least once a day, advantageously twice a day, for at least 10 days, preferably for 20 days, and more preferably for at least 28 days.
[0133] Advantageously, the topical application of the Lactobacillus crispatus strain according to the invention or of a cosmetic composition comprising the same is carried out on healthy skin and / or healthy mucous membranes of all or part of the body and / or face and / or scalp, preferably on the legs, thighs, arms, abdomen, neckline, neck, armpits or lips, more preferably on all or part of the face, and preferably on the cheeks, forehead, chin, lips or around the eyes.
[0134] In an advantageous embodiment of the cosmetic method according to the invention, the cosmetic composition comprises, relative to the total weight of the composition, between 1×10 -4 % and 10% (w / w), preferably between 1×10 -4 % and 5% (w / w), more preferably between 1×10 -3 The composition further comprises a cosmetically acceptable excipient.
[0135] The cosmetic care method according to the invention aims to reduce the pigmentation of the skin and / or mucous membranes and / or prevent its increase, in particular to maintain and / or improve the skin color of healthy skin and / or healthy mucous membranes, preferably to maintain and / or improve the glossiness and / or brightness and / or uniformity of the skin color of healthy skin and / or healthy mucous membranes, and / or to prevent the appearance of pigment spots on healthy skin and / or healthy mucous membranes and / or to reduce the presence of pigment spots on healthy skin and / or healthy mucous membranes, and advantageously comprises the following steps:
[0136] - identifying areas of healthy skin and / or healthy mucous membranes of an individual for which it is desired to reduce the pigmentation of the skin and / or mucous membranes and / or prevent its increase, in particular to maintain and / or improve the skin color of the healthy skin and / or healthy mucous membranes, preferably to maintain and / or improve the radiance and / or brightness and / or evenness of the skin color of the healthy skin and / or healthy mucous membranes, and / or to prevent the appearance of pigmented spots on the healthy skin and / or healthy mucous membranes and / or to reduce the presence of pigmented spots on the healthy skin and / or healthy mucous membranes, and
[0137] - applying topically to the area of healthy skin and / or healthy mucous membranes a cosmetic composition comprising a Lactobacillus crispatus strain according to the invention in an amount effective for reducing the pigmentation of the skin and / or mucous membranes and / or preventing its increase, in particular for maintaining and / or improving the skin color of healthy skin and / or healthy mucous membranes, preferably for maintaining and / or improving the gloss and / or brightness and / or uniformity of the skin color of healthy skin and / or healthy mucous membranes, and / or for preventing the appearance of pigmented spots on healthy skin and / or healthy mucous membranes and / or reducing the presence of pigmented spots on healthy skin and / or healthy mucous membranes, i.e. the content of the Lactobacillus crispatus strain is advantageously between 1×10 by weight relative to the total weight of the composition. -4 % and 10% (w / w), preferably between 1×10 -4 % and 5% (w / w), more preferably between 1×10 -3 Between % and 0.5% (w / w).
[0138] For purposes of the present invention, the term "topically and / or orally acceptable" means ingredients suitable for topical and / or oral application, respectively, which are non-toxic, non-irritating to the skin (including the scalp), and do not cause allergic reactions, and are chemically stable.
[0139] The subject of the present invention is also a separate Lactobacillus crispatus strain according to the invention or a pharmaceutical composition, preferably a dermatological composition, comprising this strain, which is advantageously used by topical route for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes involving hyperpigmentation and / or increased pigmentation, in particular a reduction in the radiance and / or brightness and / or evenness of the skin color of the pathological skin and / or pathological mucous membranes, and / or an increase in the appearance of pigmented spots on the pathological skin and / or pathological mucous membranes, and / or an increase in the melanogenic activity of the pathological skin and / or pathological mucous membranes, including in particular an increase in melanin and / or tyrosinase activity, and / or an increase in oxidative stress.
[0140] In particular, a subject of the present invention is a Lactobacillus crispatus strain according to the invention or a pharmaceutical composition comprising this strain, preferably a dermatological composition, which is advantageously used by topical route for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmenting pathological skin and / or pathological mucous membranes and / or preventing hyperpigmentation of pathological skin and / or pathological mucous membranes, and / or for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with oxidative stress.
[0141] The subject of the present invention is also a method for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes involving hyperpigmentation and / or increased pigmentation, in particular a reduction in the radiance and / or brightness and / or evenness of the skin color of the pathological skin and / or pathological mucous membranes, and / or an increase in the appearance of pigmented spots in the pathological skin and / or pathological mucous membranes, and / or an increase in the melanogenic activity of the pathological skin and / or pathological mucous membranes, including in particular an increase in melanin and / or tyrosinase activity, and / or an increase in oxidative stress, said method comprising administering, advantageously topically, in a subject in need thereof, in a pharmaceutically effective amount, a single Lactobacillus crispatus strain according to the invention or a pharmaceutical composition (preferably a dermatological composition) comprising said strain.
[0142] In particular, the subject of the present invention is a method for treating and / or preventing pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmenting pathological skin and / or pathological mucous membranes and / or preventing hyperpigmentation of pathological skin and / or pathological mucous membranes, and / or for treating and / or preventing pathological conditions of the skin and / or mucous membranes associated with oxidative stress, said method comprising administering, advantageously topically, a Lactobacillus crispatus strain according to the invention or a pharmaceutical composition (preferably a dermatological composition) comprising this strain in a subject in need thereof in a pharmaceutically effective amount.
[0143] The subject of the present invention is also the use of a Lactobacillus crispatus strain according to the invention alone or of a pharmaceutical composition, preferably a dermatological composition, comprising the strain for the preparation of a medicament, advantageously for topical application, for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes involving hyperpigmentation and / or increased pigmentation, in particular a reduction in the radiance and / or brightness and / or evenness of the skin color of the pathological skin and / or pathological mucous membranes, and / or an increase in the appearance of pigmented spots on the pathological skin and / or pathological mucous membranes, and / or an increase in the melanogenic activity of the pathological skin and / or pathological mucous membranes, including in particular an increase in melanin and / or tyrosinase activity, and / or an increase in oxidative stress,
[0144] In particular, the subject of the present invention is the use of a Lactobacillus crispatus strain according to the invention or a pharmaceutical, preferably dermatological, composition comprising the strain for the preparation of a medicament, advantageously for topical application, for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmenting pathological skin and / or pathological mucous membranes and / or preventing hyperpigmentation of pathological skin and / or pathological mucous membranes, and / or for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with oxidative stress.
[0145] For the purposes of the present invention, the expression "treatment and / or prevention of pathological conditions of the skin and / or mucous membranes for depigmentation and / or prevention of hyperpigmentation", in particular "treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmentation and / or prevention of hyperpigmentation", is to be understood from a dermatological point of view as meaning pigment disorders caused by pathological conditions of the skin and / or mucous membranes, such as Addison's disease, liver failure, purpura, melanoma, chloasma, dermatosis papulosa melanogaster described as pathological hyperpigmentation, or acne, eczema, atopic dermatitis, rosacea, couperose, erythema, preferably selected from Addison's disease, liver failure, purpura, melanoma, chloasma, dermatosis papulosa melanogaster, acne, atopic dermatitis, rosacea and erythema.
[0146] For the purposes of the present invention, the expression "treatment and / or prevention of pathological conditions of the skin and / or mucous membranes which are associated with oxidative stress" is understood to mean, from a dermatological point of view, the treatment and / or prevention of various skin diseases which are associated with excessive oxidative stress, including psoriasis, certain eczemas, acne, vitiligo or alternatively certain skin cancers, said skin diseases being preferably selected from vitiligo.
[0147] The Lactobacillus crispatus strain according to the present invention may be in the form of a pharmaceutical composition, preferably a dermatological composition, comprising at least one pharmaceutically and / or dermatologically acceptable excipient. In one embodiment of the present invention, the composition is applied topically and / or orally, preferably topically.
[0148] Advantageously, it is present in an amount of 1×10 by weight relative to the total weight of the composition. -4 % to 10% (w / w), preferably between 1×10 -4 % and 5% (w / w), more preferably between 1×10 -3 % and 0.5% (w / w) is present in a pharmaceutical composition, preferably a dermatological composition, which composition further comprises at least one pharmaceutically acceptable, preferably dermatologically acceptable excipient.
[0149] The invention will be better understood by reading the following description of the drawings and examples.
[0150] Examples of the description of the present invention are presented below. These examples are given for illustrative purposes and should in no way limit the scope of the present invention. Each example has a general scope.
[0151] The examples form part of the invention and also form part of the invention any feature which, in any way, is novel compared to any prior art when viewed as a whole in the description including the examples.
[0152] Also, in the examples, all percentages are by weight unless otherwise indicated, temperatures are in degrees Celsius unless otherwise indicated, and pressures are atmospheric unless otherwise indicated.
[0153] Examples
[0154] Example 1. Preparation of different forms of Lactobacillus crispatus
[0155] Example 1.a: Production of Lactobacillus crispatus in live intact form.
[0156] The isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in a MRS type medium (Man, Rogosa, Sharpe agar) and incubated anaerobically at 37° C. The pH was maintained at a value of pH=6 and the medium was incubated for 24 h. At the end of the incubation, the culture medium was centrifuged and the cell concentrate was freeze-dried in the presence of maltodextrin, the final amount of maltodextrin being 50% by weight (w / w) relative to the total weight of the ingredients.
[0157] Example 1.b: Production of an inactivated intact form of Lactobacillus crispatus
[0158] The isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in a MRS type medium and incubated anaerobically at 37° C. The pH was maintained at a value of pH=6 and the medium was incubated for 24 h. At the end of the incubation, the medium was centrifuged and the cell concentrate was inactivated by heating at 80° C. for 30 minutes. The cell concentrate was then resuspended in glycerol.
[0159] Example 1.c: Production of Lactobacillus crispatus bacterial lysate
[0160] The isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in a MRS type medium and incubated anaerobically at 37° C. The pH was maintained at a value of pH=6 and the medium was incubated for 24 h. At the end of the incubation, the whole was treated in a high pressure homogenizer. The lysate was then resuspended in glycerol.
[0161] Example 1.d: Generation of a secreted proteome of Lactobacillus crispatus bacteria
[0162] Isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in MRS-type medium and incubated anaerobically at 37°C. The pH was maintained at a value of pH = 6 and the medium was incubated for 24 h. At the end of the incubation, the medium was filtered to recover the bacterial secretome. The secretome was then diluted in glycerol.
[0163] Example 1.e: Production of the Lactobacillus crispatus bacterial secretory proteome in powder form
[0164] The isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in a MRS type medium and incubated anaerobically at 37°C. The pH was maintained at a value of pH = 6 and the medium was incubated for 24 h. At the end of the incubation, the medium was filtered to recover the bacterial secretory proteome. The secretory proteome was then sprayed with maltodextrin, so that the final amount of maltodextrin was 90% (w / w) relative to the total weight of the ingredients.
[0165] Example 2: Inhibition of melanin synthesis by melanocytes in the presence of a Lactobacillus crispatus strain according to the invention.
[0166] Melanocytes of B-16 mouse strain were cultured at 8000 cells / cm 2 The cells were seeded in a 96-well plate at a ratio of 1:1 and then cultured in a MEM medium (minimum essential medium) supplemented with 10% FCS (fetal calf serum) at 37° C., 5% CO 2 and 95% relative humidity for 3 days.
[0167] The medium was then removed and replaced with 200 μl of the above medium, supplemented with 1 μM NDP-α-MSH (melanin stimulating hormone analogue) used as a melanin synthesis stimulator, and in the presence of a 0.1% (w / w) concentration of the Lactobacillus crispatus strain according to Example 1.a for 5 days.
[0168] The same medium without addition of the strain according to the present invention but with addition of 1 μM NDP-α-MSH or addition of 0.01% (w / w) kojic acid was used as an operational control (as a melanin stimulator control and a melanin inhibitor control, respectively).
[0169] The same medium without addition of the strain according to the present invention but with ethanol was used as a control (Control).
[0170] After 5 days of incubation, cells were lysed with sodium hydroxide (NaOH) or potassium hydroxide (KOH) solution. The absorbance was measured at 475 nm.
[0171] The amount of melanin was derived from a standard range curve consisting of various concentrations of commercial synthetic melanin.
[0172] The absorbance results were normalized to the absorbance obtained with the same cell culture medium in the absence of the Lactobacillus crispatus strain according to the invention (control). The results given correspond to the mean of 6 replicates (n=6).
[0173] result
[0174]
[0175] The Lactobacillus crispatus strain according to Example 1.a, which is a product of the present invention, shows a significant inhibition of melanin synthesis of 52% of melanocytes of the murine line B-16 cultured in vitro. Therefore, the strain can be used to reduce pigmentation of the skin and / or mucous membranes and / or prevent its increase.
[0176] Example 3: Inhibition of tyrosinase activity in the presence of a Lactobacillus crispatus strain according to the invention.
[0177] Tyrosinase is a key enzyme in the process of synthesizing melanin, which is responsible for skin color. The tyrosinase used is extracted from normal human melanocytes.
[0178] The Lactobacillus crispatus strain according to Example 1.e at a concentration of 0.05% (w / w) or the reference compound (kojic acid) at a concentration range of 0.25 mM to 8 mM was pre-incubated with the enzyme on ice for 10 minutes. The tyrosinase substrate, i.e. L-tyrosine at a final concentration of 1 mM, was then added to the medium and the plates were incubated at 37°C for 24 hours.
[0179] The same enzyme extract without addition of the strain according to the invention but with ethanol was used as control (Control).
[0180] Enzyme activity was assessed by measuring the production of melanin by optical density (OD) at 540 nm using a microplate reader.
[0181] Optical density measurements were also performed without addition of substrate (n=1) to detect any interference of the Lactobacillus crispatus strain according to Example 1.e or of the reference compound (for each tested concentration).
[0182] The inhibition percentage of tyrosinase activity was calculated according to the following formula:
[0183] % inhibition: 100-[OD value / average OD of control x 100]
[0184] All experimental conditions were performed with n = 3. Comparisons between groups were performed by unpaired Student's t-test.
[0185]
[0186] The Lactobacillus crispatus strain according to Example 1.e of the present invention showed a significant inhibition of 99% of the tyrosinase activity extracted from human melanocytes. Therefore, due to this inhibition of tyrosinase activity, the Lactobacillus crispatus strain can be used to reduce pigmentation of the skin and / or mucous membranes and / or prevent its increase.
[0187] Example 4: Inhibition of melanin synthesis in a co-culture of melanocytes and keratinocytes in the presence of a Lactobacillus crispatus strain according to the invention.
[0188] Normal human keratinocytes and newborn human melanocytes were cultured at 20,000 cells / 2 and 10 000 cells / cm 2 After seeding, the cells were cultured for 7 days at 37° C., 5% CO 2 and 95% relative humidity in a 50% / 50% (v / v) mixture of a medium for melanocytes and a medium for keratinocytes supplemented with growth factors.
[0189] After one week of culture, the medium was replaced with a mixture of DMEM medium (Dulbecco's modified minimum essential Eagle's medium) without antibiotics and melanocyte medium without growth factors, and supplemented with 40 μM oleic acid.
[0190] This culture medium without addition of the strain according to the present invention was used as an untreated control (Control).
[0191] The secretome of the Lactobacillus crispatus bacterium obtained according to Example 1.e was added to the same culture medium at a concentration of 0.1% (w / w) relative to the total weight of the culture medium and the secretome.
[0192] The same medium without the strain but in the presence of 0.002% (w / w) rucinol was used as a positive control.
[0193] The culture was continued at 37°C under 5% CO2 and at 95% relative humidity for 72h, and then the culture medium was renewed. After another 48h of cultivation, the culture medium was removed and the cells were rinsed with PBS (phosphate buffered saline). Then a 1N sodium hydroxide solution containing 10% dimethyl sulfoxide (DMSO) was added to each cup of the plate. 200 μl in each cup was transferred to a transparent plate. The optical density reflecting the amount of melanin was read at 475nm.
[0194] The results are the mean ± standard deviation of the determinations performed, expressed as a percentage relative to the untreated control normalized to 100%. The statistical analysis of the results was performed relative to the untreated control using a one-way ANOVA test.
[0195] result
[0196]
[0197] The Lactobacillus crispatus strain according to example 1.e of the present invention showed a significant reduction of 32% in melanin synthesis in melanocytes co-cultured in vitro with human skin keratinocytes. Therefore, the Lactobacillus crispatus strain, and in particular its secretome, can be used to reduce pigmentation of the skin and / or mucous membranes and / or prevent its increase.
[0198] Example 5: Reduction of oxidative stress in the presence of a Lactobacillus crispatus strain according to the invention
[0199] Example 5.a: Reduction of DPPH° radical formation in tubes in the presence of a Lactobacillus crispatus strain according to the invention.
[0200] The free radical scavenging activity of Lactobacillus crispatus strains was evaluated by using the DPPH° (2,2-diphenyl-1-picrylhydrazyl) test.
[0201] The Lactobacillus crispatus strain according to Example 1.a was mixed in PBS (phosphate buffered saline) at a concentration of 0.05% (w / w) and the Lactobacillus crispatus strain according to Example 1.e was mixed in PBS (phosphate buffered saline) at a concentration of 0.7% (w / w).
[0202] A negative control was performed using PBS, a solvent used to dissolve the strain, and a positive control was performed using 1 mM vitamin C.
[0203] In the wells of a 96-well plate, each of the solutions containing the present invention, the negative control or the positive control was mixed in the DPPH° solution at 50% / 50% (v / v).
[0204] Each of the solutions containing the present invention, negative control or positive control was also mixed 50% / 50% (v / v) in ethanol solution as DPPH° solvent to create a blank in the same plate.
[0205] The whole was incubated for 30 minutes under stirring. At the end of the incubation, the optical density (OD) was measured at a wavelength of 530 nm to estimate the amount of free radicals formed under each tested condition.
[0206] The results of the measurements of the DPPH° free radicals for obtaining the free radical scavenging activity of the invention are the average of 6 tests (n=6) and are expressed as a mean percentage + / - one standard deviation. The product of the invention was compared with its negative control (PBS alone in the absence of the Lactobacillus crispatus strain). The vitamin C positive control was compared with its negative control water. Statistical analysis was performed by one-way ANOVA analysis of variance for the invention and by Student's test for vitamin C.
[0207]
[0208] The Lactobacillus crispatus strain according to Example 1.a of the present invention showed a significant free radical scavenging activity of 34% in the tube. The Lactobacillus crispatus strain according to Example 1.e of the present invention showed a free radical scavenging activity of 31% in the tube. Through this effect of reducing the production of free radicals, the Lactobacillus crispatus strain can therefore be used to detoxify the skin and / or mucous membranes, reduce pigmentation of the skin and / or mucous membranes and / or prevent its increase.
[0209] Example 5.b: Reduction of UV-induced cellular free radical release in fibroblasts in the presence of a Lactobacillus crispatus strain according to the invention.
[0210] “Normal” human fibroblasts, i.e., fibroblasts that do not display any pathological conditions, derived from healthy donors were cultured at 30,000 cells / cm 2 The cells were seeded in a 24-well plate at a ratio of 1:1 and then cultured at 37° C., 5% CO 2 and 95% relative humidity in DMEM (Dulbecco's modified minimum essential Eagle's medium) / Ham's F-12 medium supplemented with 10% FCS and 0.5% antibiotics for 96 h.
[0211] 0.5 ml of the cell suspension was then incubated for 72 h in EMEM medium (Eagle's Minimum Essential Medium) supplemented with 1% FCS and 0.5% antibiotics in the presence of a 0.0125% (w / w) concentration of the Lactobacillus crispatus strain according to Example 1.a or an antioxidant control (0.0003% (v / v) of vitamin E).
[0212] This medium without addition of the strain according to the invention was used as untreated control (UVA alone control - oxidative stress control).
[0213] The cells were incubated with 10 μM DCFH-DA (2′,7′-dichlorodihydrofluorescein diacetate) probe dissolved in PBS (phosphate buffered saline). After the first hour of incubation at 37°C in 5% CO2 and 95% relative humidity, the cells were rinsed with PBS and irradiated with UVA at 20 J / cm 2Irradiation was performed for 3 hours. Non-irradiated controls were also performed. After irradiation, the irradiated medium was removed and the cells were rinsed with PBS.
[0214] Fluorescence readings on the cell layer associated with the formation of DCF (2',7-dichlorofluorescein) using the probe (DCFH-DA) were taken at 485 nm excitation and 538 nm emission.
[0215] Results are the mean of 12 replicates (n=12) and are expressed as + / - one standard deviation. Results were compared to the UVA alone control normalized to 100% and statistically compared using one-way ANOVA analysis of variance test.
[0216]
[0217] The Lactobacillus crispatus strain according to Example 1.a of the present invention showed a significant reduction of 56% of the intracellular free radical release induced by UVA oxidative stress at the cellular level. Therefore, due to this effect of reducing the intracellular free radical release induced by UVA, the Lactobacillus crispatus strain can be used to detoxify the skin and / or mucous membranes and / or maintain and / or improve the gloss and / or brightness and / or uniformity of the skin and / or mucous membranes, preferably reduce the presence of pigment spots on the skin and / or mucous membranes and / or prevent the appearance of pigment spots on the skin and / or mucous membranes, especially when the latter are subjected to oxidative stress (preferably caused by UVA).
[0218] Example 5.c: Reduction of membrane lipid peroxidation induced by UV in fibroblasts in the presence of a Lactobacillus crispatus strain according to the invention.
[0219] “Normal” human fibroblasts, i.e., fibroblasts that do not display any pathological conditions, derived from healthy donors were cultured at 30,000 cells / cm 2 The cells were seeded in a 24-well plate at a ratio of 1:1 and then cultured at 37° C., 5% CO 2 and 95% relative humidity in DMEM / Ham's F-12 medium supplemented with 10% FCS and 0.5% antibiotics for 96 h.
[0220] 0.5 ml of the cell suspension was then incubated for 72 h in the presence of a 0.00625% (w / w) concentration of the Lactobacillus crispatus strain according to Example 1.a or an antioxidant control (0.0003% (v / v) of Vitamin E) in EMEM medium supplemented with 1% FCS and 0.5% antibiotics.
[0221] This culture medium, without addition of the strain according to the invention, was used as untreated control (after irradiation, constituting a separate UVA control - oxidative stress control).
[0222] After the first hour of incubation at 37°C, 5% CO2 and 95% relative humidity, the cells were rinsed with PBS and irradiated with UVA at 20 J / cm 2 Irradiation was performed for 3 hours. Non-irradiated controls were also performed. After irradiation, the supernatant was recovered and the cells were rinsed with PBS.
[0223] The supernatant in an amount of 0.5 ml was transferred to a Pyrex glass tube, to which a solution of 40% trichloroacetic acid and 2% thiobarbituric acid was added. The obtained mixture was heated at 100° C. for 30 minutes. The formation of MDA (malondialdehyde), an oxidation product released after UVA-induced lipid peroxidation, was then measured by fluorescence at 532 nm excitation and 560 nm emission.
[0224] Results are the mean of the measurements performed and are expressed as mean + / - one standard deviation. Results were compared to the UVA alone control normalized to 100% and statistically compared using one-way ANOVA analysis of variance test.
[0225]
[0226] The Lactobacillus crispatus strain according to Example 1.a of the present invention showed a significant reduction of 32% in the formation of MDA induced by UVA at the cellular level. Therefore, due to this effect of reducing lipid peroxidation in the presence of UV-induced stress, the Lactobacillus crispatus strain can be used to detoxify the skin and / or mucous membranes, in particular when they are subjected to oxidative stress, in particular UVA-induced stress.
[0227] Example 6: Stimulation of cellular antioxidant defenses after UV irradiation in fibroblasts in the presence of the Lactobacillus crispatus strain of the invention.
[0228] “Normal” human fibroblasts, i.e., fibroblasts that do not display any pathological conditions, derived from healthy donors were cultured at 30,000 cells / cm 2 The cells were seeded in a 24-well plate at a ratio of 1:1 and then cultured at 37° C., 5% CO 2 and 95% relative humidity in DMEM / Ham's F-12 medium supplemented with 10% FCS and 0.5% antibiotics for 96 h.
[0229] This culture medium, without addition of the strain according to the invention, was used as untreated control (after irradiation, constituting a separate UVA control - oxidative stress control).
[0230] 0.5 ml of the cell suspension was then incubated for 72 h in EMEM medium supplemented with 1% FCS and 0.5% antibiotics in the presence of a 0.0125% (w / w) concentration of the Lactobacillus crispatus strain according to Example 1.a or an antioxidant control (0.0003% (v / v) of vitamin E).
[0231] After the first hour of incubation at 37°C, 5% CO2 and 95% relative humidity, the cells were rinsed with PBS and irradiated with UVA at 20 J / cm 2 Irradiation was performed for 3 hours. Non-irradiated controls were also performed. After irradiation, the irradiated medium was removed and the cells were rinsed with PBS.
[0232] To each cup, 1N sodium hydroxide (NaOH) was added, followed by a solution diluted to 1 / 15 in GSH buffer (reduced L-glutathione). th The whole was incubated at ambient temperature for 15 minutes. The amount of glutathione was then measured by fluorescence at 355 nm excitation and 430 nm emission.
[0233] Results are the mean of the measurements performed and are expressed as mean + / - one standard deviation. Results were compared to the UVA alone control normalized to 100% and statistically compared using one-way ANOVA analysis of variance test.
[0234]
[0235] The Lactobacillus crispatus strain of example 1.a according to the invention showed a significant increase in cellular antioxidant defences by a 54% increase in glutathione after irradiation with UVA.
[0236] Therefore, due to this effect of increasing the cellular antioxidant defences in the presence of UV-induced oxidative stress, Lactobacillus crispatus strains can be used to detoxify the skin and / or mucous membranes, in particular when they are subjected to oxidative stress, in particular UVA-induced stress.
[0237] Example 7: In vivo measurement of the reduction in the amount of melanin in the skin in the presence of a Lactobacillus crispatus strain according to the invention.
[0238] A group of 30 Chinese women of phototype II to IV, aged 40 to 50 years with pigmented spots on their faces, were applied to half of their faces with a cream in the form of an emulsion, the cream comprising the Lactobacillus crispatus strain according to Example 1.e at the following final concentration: 1% (w / w) by weight relative to the total weight of the cream (formulation of Example 8.b), or without the extract, the extract having been replaced with water (placebo), and the emulsion was applied at a rate of 2 applications per day for 2 months.
[0239] The assessment of the melanin content of the skin is carried out using a device called a mexameter, which uses the absorption / reflection principle. From the mexameter measurements a melanin index is derived. A decrease in this index corresponds to a decrease in melanin.
[0240] The efficacy of a composition containing the Lactobacillus crispatus strain according to Example 1.e was compared with the efficacy of a "placebo" lotion.
[0241] The melanin index was measured at the beginning of the study (D0), after one month of application (D28) and finally, after 2 months of application (D56).
[0242] The efficacy of the formulations containing the Lactobacillus crispatus strain according to Example 1.e and the efficacy of the placebo formulation were expressed as mean values and compared with the values at the beginning of the study (D0) and compared between the formulations containing the Lactobacillus crispatus strain and the formulation containing the placebo using the Student's test or the Wilcoxon test.
[0243]
[0244] The formulation of the Lactobacillus crispatus strain according to Example 1.e significantly reduced the amount of skin melanin as measured by the Melanin Index using a skin pigmentation meter.
[0245] These results show the beneficial effect of a Lactobacillus crispatus strain formulated to maintain and / or improve the radiance and / or brightness and / or uniformity of healthy skin and / or healthy mucous membranes.
[0246] Example 8: Example of a cosmetic composition comprising a Lactobacillus crispatus strain according to the present invention
[0247] Example 8.a: Example of a cosmetic composition comprising the Lactobacillus crispatus strain according to Example 1.a
[0248] Immediately before application to the skin, the Lactobacillus crispatus strain obtained according to Example 1.a is added to the formulation defined below according to Table 8 at a final concentration of 0.05% (w / w) relative to the total weight of the formulation.
[0249]
[0250]
[0251] Example 8.b: Example of a cosmetic composition comprising the Lactobacillus crispatus strain according to Example 1.e. The proportions are expressed as percentages and the names in capital letters correspond to the INCI names of the ingredients.
[0252]
[0253]
[0254] Phases A, B and C are mixed together at ambient temperature using methods known to those skilled in the art by adding B to A under stirring and then adding C to AB. The pH is adjusted to 4.9 with D. Phase E is then added. Finally, homogenization is performed with an Ultra-Turrax stirrer to prepare the composition according to the invention.
[0255]
Claims
1. Cosmetic and / or nutritional use of a Lactobacillus crispatus strain, preferably of the species deposited under the name CNCM I-5579, for reducing pigmentation of the skin and / or mucous membranes and / or preventing its increase.
2. Use as claimed in claim 1, wherein the strain reduces and / or inhibits melanin production, in particular by acting on the reduction and / or inhibition of melanin, preferably on the reduction and / or inhibition of the synthesis and / or amount of melanin, and / or by reducing and / or inhibiting tyrosinase activity, and / or by detoxifying healthy skin and / or healthy mucous membranes.
3. Use according to any one of the preceding claims for maintaining and / or improving the complexion of healthy skin and / or healthy mucous membranes.
4. Use according to any of the preceding claims for maintaining and / or improving the radiance and / or brightness and / or evenness of the complexion of healthy skin and / or healthy mucous membranes.
5. The use according to any one of the preceding claims, for preventing the appearance and / or reducing the presence of pigmented spots, preferably brown spots and / or age spots, on healthy skin and / or healthy mucous membranes.
6. Use according to any one of the preceding claims for detoxifying healthy skin and / or healthy mucous membranes, in particular by an antioxidant action and / or an action on lipid peroxidation and / or by an increase and / or stimulation of the synthesis of glutathione induced by oxidative stress.
7. Use according to any of the preceding claims, wherein the strain is used in intact form, in particular alive and / or inactivated, in particular dead, and / or in the form of a lysate, and / or in the form of one or more fractions thereof, and / or in the form of one or more metabolites thereof, preferably its secretome.
8. The use according to any one of the preceding claims, wherein the Lactobacillus crispatus strain is the strain deposited under number CNCM 1-5579.
9. Use according to one of the preceding claims, wherein the Lactobacillus crispatus strain is used in live intact form and / or in the form of one or more of its metabolites, preferably its secretome.
10. Use according to one of the preceding claims, wherein the Lactobacillus crispatus strain is combined with its culture medium.
11. The use according to one of the preceding claims, wherein the Lactobacillus crispatus strain is applied topically to healthy skin and / or healthy mucous membranes.
12. The use according to claim 11, wherein the skin is phototype IV to VI.
13. The use according to any one of the preceding claims, wherein the Lactobacillus crispatus strain is present in the cosmetic composition at a concentration of 1×10 by weight relative to the total weight of the composition. -4 % to 10%, preferably between 1×10 -4 % and 5%, and more advantageously between 1×10 -3 % and 0.5%, the composition further comprises at least one cosmetically acceptable excipient.
14. A beauty care method, characterized in that The method comprises topically applying to at least one area of healthy skin and / or healthy mucous membranes a Lactobacillus crispatus strain as defined in one of claims 7 to 10 or a cosmetic composition as claimed in claim 13, for reducing pigmentation of the skin and / or mucous membranes and / or for preventing its increase, in particular for maintaining and / or improving the skin color of healthy skin and / or healthy mucous membranes, preferably for maintaining and / or improving the gloss and / or brightness and / or uniformity of the skin color of healthy skin and / or healthy mucous membranes, and / or for preventing the appearance and / or reducing the presence of pigmented spots on healthy skin and / or healthy mucous membranes, and / or for detoxifying the skin and / or mucous membranes.
15. A cosmetic care method according to claim 14, wherein the topical application of the Lactobacillus crispatus strain as defined in one of claims 7 to 10 or the cosmetic composition according to claim 13 is carried out on healthy skin and / or healthy mucous membranes of all or part of the body and / or face and / or scalp, preferably on the legs, thighs, arms, abdomen, neckline, neck, armpits, lips, more preferably on all or part of the face, and preferably on the cheeks, forehead, chin, lips, around the eyes.
16. A cosmetic treatment method according to any one of claims 14 and 15, wherein the cosmetic composition comprises a Lactobacillus crispatus strain as defined in one of claims 7 to 10 at a concentration of 1×10 by weight relative to the total weight of the composition. -4 % to 10%, preferably between 1×10 -4 % and 5%, more preferably between 1×10 -3 % and 0.5%, the composition further comprises at least one cosmetically acceptable excipient.
17. A Lactobacillus crispatus strain or a pharmaceutical composition comprising the strain, preferably a dermatological composition, which is advantageously used by topical route for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with increased pigmentation of the skin and / or mucous membranes, in particular for depigmenting pathological skin and / or pathological mucous membranes and / or preventing hyperpigmentation of pathological skin and / or pathological mucous membranes, and / or for the treatment and / or prevention of pathological conditions of the skin and / or mucous membranes associated with oxidative stress.
18. The strain as claimed in claim 17, wherein the strain is used in intact form, in particular alive and / or inactivated, in particular dead, and / or in the form of a lysate, and / or in the form of one or more fractions thereof, and / or in the form of one or more metabolites thereof, preferably its secretome, and / or wherein the strain is combined with its culture medium.
19. The Lactobacillus crispatus strain for use according to any one of claims 17 and 18, characterized in that The strain is in the form of a pharmaceutical composition, preferably a dermatological composition, comprising at least one dermatologically acceptable excipient.
20. The Lactobacillus crispatus strain for use according to any one of claims 17 to 19, characterized in that The strain is present in the pharmaceutical composition, preferably the dermatological composition, at a concentration of 1×10 by weight relative to the total weight of the composition. -4 % to 10%, preferably between 1×10 -4 % and 5%, more preferably between 1×10 -3 % and 0.5%, the composition further comprises at least one pharmaceutically, preferably dermatologically acceptable excipient.
21. The Lactobacillus crispatus strain for use according to any one of claims 17 to 20, characterized in that The strain is as defined in one of claims 7 to 10.
